NYXH Nyxoah SA
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for …
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 CVRx names John Landry as CFO Landry joins in the aftermath of an investor’s call for the sale of the heart failure device company. | ||
 Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption? Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 […] | ||
 Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval. | ||
Nyxoah Shares Jump After Genio Meets Primary Endpoints in CCC Patient Study Nyxoah SA (NYXH) shares jumped 15% in Wednesday trading after it said its ACCCESS US pivotal study m | ||
Nyxoah SA (NYXH) (Q2 2026) Earnings Call Highlights: US Revenue Surges 22% Sequentially, $110M ... Nyxoah SA (NYXH) reports strong US commercial momentum with active accounts doubling to 180, while securing capital to accelerate its launch ramp. | ||
 Nyxoah Q2 Earnings Call Highlights Nyxoah (NASDAQ:NYXH) reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequen | ||
LLe Soleil | ||